Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
{{output}}
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be app... ...
